Skip to main content
Evidence Snapshot

Casein kinase II subunit alpha

CHEMBL3629 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:39:33Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3629
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Casein kinase II subunit alpha as ChEMBL target CHEMBL3629, mapped to UniProt P68400. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Casein kinase II subunit alpha
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3629
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P68400
Casein kinase II subunit alpha
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Casein kinase II subunit alpha matters

As of 2026-09-13

Casein kinase II subunit alpha is reviewed as Casein kinase II subunit alpha (UniProt P68400); Casein kinase II subunit alpha shows clinical signal disease relevance led by COVID-19. 4 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 8 approved drugs, 2617 compounds, and 666 assays, with lead potency reaching pChEMBL 10.9.

Disease context
COVID-19

Casein kinase II subunit alpha shows clinical signal disease relevance led by COVID-19. 4 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 4 additional disease programs remain visible in the same card. Linked drugs include SILMITASERTIB.

Start review with COVID-19 because it currently carries clinical signal support. Linked drugs include SILMITASERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 8 approved drugs, 2617 compounds, and 666 assays for this target. The dominant activity type is IC50. CHEMBL4089961 is the current potency anchor at pChEMBL 10.9.

Use CHEMBL4089961 as the tractability anchor when discussing potency (pChEMBL 10.9).

Activity source · ChEMBL 36 via Core Engine
8 approved pChEMBL 10.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Casein kinase II subunit alpha matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P68400, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why COVID-19 is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2617
Total Compounds
666
Total Assays
8
Approved Drugs
IC50: 1620.0, KI: 869.0, EC50: 2.0, KD: 200.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4089961
 10.9 Kd —
No preferred name
CHEMBL4077554
 10.5 Kd —
No preferred name
CHEMBL3103191
 10.3 Kd —
No preferred name
CHEMBL4099729
 10.0 Kd —
No preferred name
CHEMBL3699289
 9.9 IC50 —

Approved Drugs

Structure Compound First Approval
BELUMOSUDIL
CHEMBL2005186
 2021
FEDRATINIB
CHEMBL1287853
 2019
ABEMACICLIB
CHEMBL3301610
 2017
MIDOSTAURIN
CHEMBL608533
 2017
PALBOCICLIB
CHEMBL189963
 2015
SUNITINIB
CHEMBL535
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:39:33Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3629